Background Disease modifying treatments (DMTs) have transformed the management of people with MS (pwMS). However, patients an EDSS>6.5 (pwAMS) are considered beyond DMT due to (i) focus on ambulation as outcome measure, (ii) assumption that in pwAMS inflammation plays no role, and (iii) disregard for potentially length-dependent neuro-axonal damage. Cladribine is a CNS penetrant, effective, ...